VYNE Therapeutics Announces Phase 1a SAD Data For VYN202, A Novel BD2-Selective BET Inhibitor; VYN202 Was Generally Well Tolerated With No Drug-Related Adverse Events
Portfolio Pulse from Benzinga Newsdesk
VYNE Therapeutics announced positive Phase 1a SAD trial results for VYN202, a BD2-selective BET inhibitor. The drug was well tolerated with no adverse events, showing dose-dependent exposure and pharmacodynamic activity. The MAD trial phase has begun, with results expected in Q4 2024.
September 12, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VYNE Therapeutics' VYN202 showed positive Phase 1a SAD trial results, indicating good tolerance and promising pharmacokinetics. This could boost investor confidence as the MAD trial phase progresses.
The positive Phase 1a SAD trial results for VYN202, with no adverse events and promising pharmacokinetics, are likely to boost investor confidence in VYNE Therapeutics. The initiation of the MAD trial phase and expected results in Q4 2024 further support a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100